Neutralizing antibody titers to Omicron six months after vaccination with BNT162b2 in Colombia

dc.creatorZapata Cardona, María Isabel
dc.creatorFlórez Álvarez, Lizdany
dc.creatorLopera Restrepo, Tulio José
dc.creatorMedina Chvatal, Mateo
dc.creatorZapata Builes, Wildeman
dc.creatorDíaz Castrillón, Francisco Javier
dc.creatorAguilar Jiménez, Wbeimar
dc.creatorTaborda Vanegas, Natalia Andrea
dc.creatorHernández López, Juan Carlos
dc.creatorRugeles López, María Teresa
dc.date2023-06-13T19:21:07Z
dc.date2023-06-13T19:21:07Z
dc.date2022
dc.date.accessioned2024-04-23T17:38:30Z
dc.date.available2024-04-23T17:38:30Z
dc.identifierZapata-Cardona MI, Flórez-Álvarez L, Lopera TJ, Chvatal-Medina M, Zapata-Builes W, Diaz FJ, Aguilar-Jimenez W, Taborda N, Hernandez JC, Rugeles MT. Neutralizing antibody titers to Omicron six months after vaccination with BNT162b2 in Colombia. Front Immunol. 2022 Dec 21;13:1102384. doi: 10.3389/fimmu.2022.1102384. PMID: 36618393; PMCID: PMC9811190.
dc.identifier1664-3224
dc.identifierhttps://hdl.handle.net/10495/35478
dc.identifier10.3389/fimmu.2022.1102384
dc.identifier1664-3224
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/9229622
dc.descriptionABSTRACT:The emergence of the Omicron variant has generated concerns about the efficacy of COVID-19 vaccines. We evaluated the serum neutralizing activity of antibodies against the Omicron (lineage BA.1.1) by plaque reduction neutralizing test, as well as its correlation with age and gender, in a Colombian cohort six months after being vaccinated with BNT162b2 (Pfizer/BioNTech). Compared to all other variants analyzed, a significantly lower neutralizing activity (p<0.001) was observed against Omicron. Interestingly, older individuals exhibited lower titers against Omicron than those younger than 40. No statistical differences in neutralizing activity were observed according to gender. Our results showed that two doses of BNT162b2 might not provide robust protection against the Omicron variant over time. It is necessary to consider including changes in the composition of the vaccines to protect against new emerging variants of SARS-CoV-2 and campaigns to implement additional booster vaccinations
dc.descriptionCOL0012444
dc.format6
dc.formatapplication/pdf
dc.formatapplication/pdf
dc.languageeng
dc.publisherLausanne : Frontiers Research Foundation
dc.publisherInmunovirología
dc.publisherSuiza
dc.relationFront. Immunol.
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightshttp://creativecommons.org/licenses/by/2.5/co/
dc.rightshttp://purl.org/coar/access_right/c_abf2
dc.rightshttps://creativecommons.org/licenses/by/4.0/
dc.subjectSARS-CoV-2
dc.subjectEnfermedades Transmisibles
dc.subjectCommunicable Diseases
dc.subjectAnticuerpos Neutralizantes
dc.subjectAntibodies, Neutralizing
dc.subjectInformes de Casos
dc.subjectCase Reports
dc.subjectVacuna BNT162 - Colombia
dc.subjectBNT162 Vaccine - Colombia
dc.titleNeutralizing antibody titers to Omicron six months after vaccination with BNT162b2 in Colombia
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typehttp://purl.org/coar/resource_type/c_2df8fbb1
dc.typehttps://purl.org/redcol/resource_type/ART
dc.typeArtículo de investigación


Este ítem pertenece a la siguiente institución